A new CAR T therapy design uses the approved drug venetoclax to temporarily disengage engineered immune cells from tumors.

Among the most promising tools of cancer therapy, engineered immune cells known as chimeric antigen-receptor (CAR) T cells have already transformed the treatment of blood cancers. Yet, despite their ...

Cancer tumors hijack the vagus nerve to communicate with the brain, triggering a hormonal response that suppresses the immune system.

Scientists have uncovered an unexpected reason why some cancers return after initially responding to treatment.

A pioneering clinical trial is exploring whether lab-engineered stem cells can restore dopamine production in people with Parkinson’s disease.

A new study published by Mayo Clinic researchers suggests that ovarian cancer cells quickly activate a survival response after PARP inhibitor treatment, and blocking this early response may make this ...

By Hugo Francisco de Souza A novel CAR-T cell approach targets amyloid plaques in preclinical Alzheimer models, raising the ...

Beyond the Bone Marrow İSTANBUL, BEşIKTAş, TURKEY, February 3, 2026 /EINPresswire.com/ -- How Stem Cell Transplantation ...

A genetics‑guided drug, compound 6, targets CARD9 to subtly calm gut inflammation in Crohn’s disease, pointing to safer, longer‑lasting, precision treatments.

UCSF is teaming up with Nektar to study NKTR-0165, an experimental antibody that activates the TNFR2 receptor, as a treatment ...

New findings reveal that succinate signaling through SUCNR1 acts as a protective brake in acute myeloid leukemia. Modulating ...

A new study published by Mayo Clinic researchers suggests that ovarian cancer cells quickly activate a survival response after PARP inhibitor treatment, and blocking this early response may make this ...